This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4urk
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | ''' | + | ==PI3Kg in complex with AZD6482== |
| + | <StructureSection load='4urk' size='340' side='right' caption='[[4urk]], [[Resolution|resolution]] 2.90Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4urk]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4URK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4URK FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=A82:2-[[(1R)-1-(7-METHYL-2-MORPHOLIN-4-YL-4-OXIDANYLIDENE-PYRIDO[1,2-A]PYRIMIDIN-9-YL)ETHYL]AMINO]BENZOIC+ACID'>A82</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4urk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4urk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4urk RCSB], [http://www.ebi.ac.uk/pdbsum/4urk PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Optimization of AZD6482 (2), the first antiplatelet PI3Kbeta inhibitor evaluated in man, focused on improving the pharmacokinetic profile to a level compatible with once daily oral dosing as well as achieving adequate selectivity towards PI3Kalpha to minimize the risk for insulin resistance. Structure-based design and optimization of DMPK properties resulted in (R)-16, a novel, orally bioavailable PI3Kbeta inhibitor with potent in vivo anti-thrombotic effect with excellent separation to bleeding risk and insulin resistance. | ||
| - | + | Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kbeta inhibitors, useful as antiplatelet agents.,Giordanetto F, Barlaam B, Berglund S, Edman K, Karlsson O, Lindberg J, Nylander S, Inghardt T Bioorg Med Chem Lett. 2014 Aug 15;24(16):3936-43. doi:, 10.1016/j.bmcl.2014.07.007. Epub 2014 Jul 9. PMID:25042253<ref>PMID:25042253</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Barlaam, B.]] | ||
| + | [[Category: Berglund, S.]] | ||
| + | [[Category: Edman, K.]] | ||
| + | [[Category: Giordanetto, F.]] | ||
| + | [[Category: Inghardt, T.]] | ||
| + | [[Category: Karlsson, O.]] | ||
| + | [[Category: Lindberg, J.]] | ||
| + | [[Category: Nylander, S.]] | ||
| + | [[Category: Lipid kinase]] | ||
| + | [[Category: Transferase]] | ||
Revision as of 12:30, 22 October 2014
PI3Kg in complex with AZD6482
| |||||||||||
